Embecta CORP. (EMBC) — SEC Filings

Q: What are the key financial highlights for Embecta CORP.?

Key financial highlights for Embecta CORP. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Embecta CORP.?

Key executives at Embecta CORP. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Embecta CORP. stock?

Risk factors for Embecta CORP. (EMBC) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Embecta CORP.?

Forward-looking statements and predictions from Embecta CORP. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Embecta CORP.. Recent DEF 14A filing on Dec 18, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Embecta CORP. on SEC EDGAR

Overview

Embecta CORP. (EMBC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 18, 2025: Embecta Corp. (EMBC) reported a strong fiscal year 2025, successfully completing its global ERP implementation and exceeding adjusted operating margin targets. The company reduced debt by approximately $185 million and generated strong free cash flow, creating capacity for future growth investments.

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 24 neutral, 1 mixed. The dominant filing sentiment for Embecta CORP. is neutral.

Filing Type Overview

Embecta CORP. (EMBC) has filed 2 DEF 14A, 2 10-K, 8 8-K, 6 10-Q, 8 SC 13G/A, 3 SC 13G, 1 10-K/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (30)

Embecta Shifts to 'Seed Growth,' Eyes GLP-1 Expansion After Debt Cut — DEF 14A · Dec 18, 2025 Risk: medium
Embecta Corp. (EMBC) reported a strong fiscal year 2025, successfully completing its global ERP implementation and exceeding adjusted operating margin targets.
Embecta Navigates Post-Spin-Off Landscape, Eyes Growth Beyond Diabetes — 10-K · Nov 25, 2025 Risk: medium
Embecta Corp. (EMBC) reported its fiscal year ended September 30, 2025, as a leading global medical device company focused on diabetes care. The company's produ
8-K Filing — 8-K · Nov 17, 2025
Embecta Q3 Net Sales Dip, Swings to Loss Amid Volume Declines — 10-Q · Aug 8, 2025 Risk: high
Embecta Corp. reported net sales of $269.8 million for the three months ended June 30, 2025, a decrease from $274.6 million in the prior-year period. For the ni
Embecta Corp. Files 8-K for Regulatory Disclosure — 8-K · May 22, 2025 Risk: low
Embecta Corp. filed an 8-K on May 22, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific fin
Embecta Corp. Files Q2 2025 10-Q — 10-Q · May 9, 2025 Risk: medium
Embecta Corp. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position, including assets, liabil
Embecta Corp. Files 8-K on Shareholder Vote Matters — 8-K · Feb 14, 2025 Risk: low
Embecta Corp. filed an 8-K on February 14, 2025, reporting on a submission of matters to a vote of security holders that occurred on February 12, 2025. The fili
Embecta Corp. Files Q1 2025 10-Q — 10-Q · Feb 6, 2025 Risk: low
Embecta Corp. filed its 10-Q for the period ending December 31, 2024. The company reported its financial results for the first quarter of fiscal year 2025. Spec
Embecta Corp. Files 2025 Proxy Statement — DEF 14A · Dec 19, 2024 Risk: low
Embecta Corp. filed its definitive proxy statement for its 2025 annual meeting of stockholders, scheduled for February 12, 2025. The filing, submitted on Decemb
Embecta Corp. Files 2024 Annual Report — 10-K · Dec 11, 2024 Risk: low
Embecta Corp. filed its 10-K for the fiscal year ending September 30, 2024. The company, formerly known as Berra Newco, Inc. until July 14, 2021, is a manufactu
Embecta Corp. Reports Director Departure and Officer Changes — 8-K · Dec 2, 2024 Risk: low
Embecta Corp. announced on November 26, 2024, the departure of director Michael J. De Guzman. The company also reported on the election of new directors and com
Embecta Corp. Files 8-K on Financials — 8-K · Nov 26, 2024 Risk: low
Embecta Corp. filed an 8-K on November 26, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and ex
SC 13G/A Filing — SC 13G/A · Nov 8, 2024
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
SC 13G Filing — SC 13G · Oct 25, 2024
Embecta Corp. Announces Executive and Board Changes — 8-K · Aug 12, 2024 Risk: medium
Embecta Corp. announced on August 12, 2024, changes in its executive team and board of directors. The filing details the departure of certain officers and direc
Embecta Corp. Files Q3 2024 10-Q — 10-Q · Aug 9, 2024 Risk: low
Embecta Corp. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company, formerly known as Berra Newco, Inc., is i
Embecta Corp. Files 10-Q for Q2 2024 — 10-Q · May 9, 2024 Risk: medium
Embecta Corp. (EMBC) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Embecta Corp. reported its Q2 2024 financial results on May 9, 2024. The filin
Embecta Corp. Files 10-K/A Amendment No. 1 for Fiscal Year Ended September 30, 2023 — 10-K/A · Apr 5, 2024 Risk: low
Embecta Corp. (EMBC) filed a Amended Annual Report (10-K/A) with the SEC on April 5, 2024. Embecta Corp. filed an amendment (10-K/A) to its annual report for th
Embecta Corp. Files 8-K for Material Agreement — 8-K · Mar 28, 2024 Risk: low
Embecta Corp. filed an 8-K on March 28, 2024, to report the entry into a material definitive agreement and to file financial statements and exhibits. The filing
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
American Century Discloses 6.4% Stake in Embecta Corp. — SC 13G · Feb 12, 2024 Risk: low
American Century Investment Management, Inc. reported on February 12, 2024, that as of December 31, 2023, they beneficially own 2,336,654 shares of Embecta Corp
Embecta Corp. Files 10-Q for Q1 2024 — 10-Q · Feb 9, 2024 Risk: medium
Embecta Corp. (EMBC) filed a Quarterly Report (10-Q) with the SEC on February 9, 2024. Embecta Corp. filed its 10-Q for the period ending December 31, 2023. The
FMR LLC & Abigail Johnson Trim Embecta Stake to 4.123% — SC 13G/A · Feb 9, 2024 Risk: medium
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Embecta Corp. (CUSIP #29082K105). As of Feb
Embecta Files 8-K on Shareholder Vote Submission — 8-K · Feb 9, 2024 Risk: low
Embecta Corp. filed an 8-K on February 9, 2024, reporting an event that occurred on February 7, 2024, related to the submission of matters to a vote of security
River Road Asset Management Discloses 6.1% Stake in Embecta Corp. — SC 13G · Jan 30, 2024
River Road Asset Management, LLC, a Kentucky-based investment firm, has disclosed a significant passive stake in Embecta Corp. (EMBC), a medical instruments com
State Street Corp. Updates Passive Stake in Embecta Corp. — SC 13G/A · Jan 23, 2024
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Embecta Corp. common stock a
Millennium Group's Integrated Core Strategies Updates Embecta Stake — SC 13G/A · Jan 22, 2024
Integrated Core Strategies (US) LLC, part of the Millennium Management group led by Israel A. Englander, filed an amended SC 13G/A on January 22, 2024, indicati
BlackRock Updates Passive Stake in Embecta Corp. — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 22, 2024, indicating its ownership in Embecta Corp. as of December 31, 2023. This filing updates previ

Risk Profile

Risk Assessment: Of EMBC's 20 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Devdatt (Dev) Kurdikar
Jeff Mann
LTG (Ret.) David F. Melcher
Carrie L. Anderson
Robert (Bob) J. Hombach
Milton M. Morris, Ph.D.
Claire Pomeroy, M.D.
Karen N. Prange
Michael J. De Guzman
Abigail P. Johnson

Industry Context

Embecta operates in the diabetes care and medical device market, a sector characterized by a strong legacy of innovation and a growing patient population. Key trends include the increasing prevalence of diabetes globally, the rise of new therapeutic classes like GLP-1 agonists, and a focus on affordable and accessible delivery devices. The competitive landscape includes established players and emerging companies vying for market share in both core diabetes management and adjacent growth areas.

Top Tags

institutional-ownership (6) · 10-Q (5) · financials (5) · Medical Devices (4) · corporate-governance (4) · passive-investment (4) · Diabetes Care (3) · 8-K (3) · medical-devices (3) · Embecta Corp. (3)

Executive Compensation

From the most recent DEF 14A filing (Dec 18, 2025):

Devdatt (Dev) Kurdikar — President and Chief Executive Officer

Key Numbers

Debt reduction: $185 million — Achieved in fiscal year 2025, creating capacity for future growth investments
Fiscal year: 2025 — Year of strong execution and strategic progress, including ERP implementation
Annual Meeting Year: 2026 — Meeting to be held on February 11, 2026, at 8:00 a.m. ET
Countries: 8 — Where Embecta earned Great Place to Work certification
Additional shares: 2,430,000 — Proposed increase in shares authorized for issuance under the 2022 Employee and Director Equity-Based Compensation Plan
Director nominees: 7 — Standing for election at the 2026 Annual Meeting
Independent director nominees: 6 of 7 — Reflecting strong corporate governance
Diverse board representation: 71% — Of director nominees are ethnically and/or gender diverse
Individuals served: 30 million — Currently served by Embecta's approximately 2,000 employees
Legacy: 100-year — Embecta's strong legacy in improving care for people with diabetes
Market Value of Non-Affiliate Common Equity: $732M — As of March 31, 2025, indicating significant public float.
Shares Outstanding: 58.5M — As of November 18, 2025, providing a basis for per-share metrics.
Countries Served: 100+ — Demonstrates Embecta's extensive global reach for its diabetes products.
People Using Products: 30M+ — Highlights the broad user base for Embecta's insulin administration devices.
Global Employees: 1,850 — As of September 30, 2025, indicating the company's workforce size.

Forward-Looking Statements

{"claim":"Embecta Corp. stock may experience increased investor interest due to American Century's significant stake.","entity":"Embecta Corp.","targetDate":"Q2 2024","confidence":"medium"}
{"claim":"American Century Investment Management, Inc. will maintain or slightly increase its position in Embecta Corp. over the next year.","entity":"American Century Investment Management, Inc.","targetDate":"Q1 2025","confidence":"medium"}
{"claim":"Embecta Corp. will continue to reduce its net loss in the next fiscal quarter.","entity":"Embecta Corp.","targetDate":"2024-03-31","confidence":"medium"}
{"claim":"Selling, general, and administrative expenses will remain a key focus for cost reduction efforts.","entity":"Embecta Corp.","targetDate":"2024-09-30","confidence":"high"}
{"claim":"Embecta Corp.'s stock price may experience short-term downward pressure due to the reduced institutional ownership.","entity":"Embecta Corp.","targetDate":"3 months","confidence":"medium"}

Related Companies

BDX · NVO · TRUMY

Frequently Asked Questions

What are the latest SEC filings for Embecta CORP. (EMBC)?

Embecta CORP. has 30 recent SEC filings from Jan 2024 to Dec 2025, including 8 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of EMBC filings?

Across 30 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 24 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Embecta CORP. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Embecta CORP. (EMBC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Embecta CORP.?

Key financial highlights from Embecta CORP.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for EMBC?

The investment thesis for EMBC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Embecta CORP.?

Key executives identified across Embecta CORP.'s filings include Devdatt (Dev) Kurdikar, Jeff Mann, LTG (Ret.) David F. Melcher, Carrie L. Anderson, Robert (Bob) J. Hombach and 5 others.

What are the main risk factors for Embecta CORP. stock?

Of EMBC's 20 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 12 low-risk.

What are recent predictions and forward guidance from Embecta CORP.?

Recent forward-looking statements from Embecta CORP. include guidance on {"claim":"Embecta Corp. stock may experience increased investor interest due to American Century's significant stake."," and 4 other predictions.